NewAmsterdam Pharma Company's total assets for Q2 2024 were $446.69M, a decrease of -15.97% from the previous quarter. NAMS total liabilities were $59.25M for the fiscal quarter, a -90.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.